Starving tumors

Moleculin announces new data discovery for presentation at Society for Neuro-Oncology meeting

Nov 12, 2018
DDNews Staff
HOUSTON—Moleculin Biotech Inc., a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, announced recently that new data relating to its molecule WP1122 would be presented at the Society for Neuro-Oncology Annual Scientific Meeting to be held Nov. 15-18 in New Orleans.
 
“We continue to make progress in the development of our inhibitor of glycolysis, WP1122,” commented Dr. Donald Picker, Moleculin’s chief science officer. “We believe that we have discovered new data during our IND-enabling research with animals that confirms a highly beneficial metabolism of WP1122 and significant organ accumulation of the inhibitor of glycolysis in the brain and also in the pancreas.
 
“This is especially significant because both brain and pancreatic tumors are highly dependent upon glucose for survival and WP1122 appears to have the ability to inhibit glycolysis, the process by which these tumors convert glucose into energy.”
 
Adds Walter Klemp, Moleculin’s chairman and CEO: “Metabolic inhibition of tumors is conceptually a very important approach, and we believe we have a clear translational focus. We have been pushing hard to prepare WP1122 for Investigational New Drug status. It is encouraging to have discoveries during this process that appear to confirm the initial premise and give us more hope that WP1122 could become an important new way to deal with difficult cancers like glioblastoma and pancreatic cancer.”
 
Moleculin’s clinical-stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity (being studied for the treatment of relapsed or refractory acute myeloid leukemia, or AML), and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. The company is also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.
Subscribe to our eNewsletters

Stay connected with all the latest DDN news!

Latest Issue's Magazine Cover

Latest Issue  

• Volume 17 • Issue 9 • September 2021

September 2021

September 2021 Issue